RxDoctor Payments Data

Emily Nosbisch, NP

Family · Teutopolis, ILNPI 1932686326

Payments from drug & device makers

$1,018in general payments, 2019–2025

Across 67 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$213
  • Amgen$159
  • Lilly USA, LLC$150
  • E.r. Squibb & Sons, L.L.C.$67
  • AbbVie$63
  • Boehringer Ingelheim$59
  • plus $308 from 14 others

What the payments were for

  • Food & beverage$1,018100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,018 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$5,212
Medicare patients
159
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$47,877
TrulicityDulaglutide31$29,893
JardianceEmpagliflozin28$21,293
EliquisApixaban33$20,755
MounjaroTirzepatide14$13,894
MyrbetriqMirabegron23$10,209
Repatha SyringeEvolocumab14$7,102
Mesalamine11$2,591
Celecoxib67$1,477
Levothyroxine Sodium163$1,268
Duloxetine Hcl69$1,236
Atorvastatin Calcium132$1,170
Pantoprazole Sodium69$1,017
Lisinopril141$872
Albuterol Sulfate HfaAlbuterol Sulfate35$841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$213$47,87749 claims
Lilly USA, LLCTrulicity, Mounjaro$150$43,78745 claims
Boehringer IngelheimJardiance$59$21,29328 claims
PfizerEliquis$17$20,75533 claims
Astellas Pharma US IncMyrbetriq$12$10,20923 claims
AbbVieArmour Thyroid$63$59012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,941 family providers in Illinois.

Other family in Teutopolis

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →